Multiple preclinical models have demonstrated robust synergy between PARP inhibitors and PD-1/PD-L1 antagonists, resulting in durable tumor regression and expansion of CD8+ T-cell repertoires [117,118,119,120]. Here, CD8A is linked to neoplasm.